aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod
aTyr Pharma Inc ATYR
$0.49
▲ +1.19%
(+$0.01)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$0.50
Prev Close
$0.48
Day Range
$0.47 – $0.50
52W Range
$0.40 – $6.50
Market Cap
$47.62M
Beta
0.53
EPS (TTM)
$-0.80
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-05-07 |
| Shares Out. | 98,050,000 |
| Website | atyrpharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 58 |
| Net Income | -$10.8M |
| Free Cash Flow | -$59.3M |
| Total Assets | $79.7M |
| Total Liabilities | $21.9M |
| Equity | $57.7M |
About aTyr Pharma Inc
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
aTyr Pharma Inc is a publicly traded company under the ticker symbol ATYR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)